## Christina Antza

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/78814/publications.pdf

Version: 2024-02-01

623734 642732 44 620 14 23 citations g-index h-index papers 45 45 45 882 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Endocrine, 2022, 76, 324-330.	2.3	4
2	Sleep behaviours and associated habits and the progression of pre-diabetes to type 2 diabetes mellitus in adults: A systematic review and meta-analysis. Diabetes and Vascular Disease Research, 2022, 19, 147916412210888.	2.0	7
3	Arterial stiffness in children and adolescents with masked and sustained hypertension. Journal of Human Hypertension, 2021, 35, 85-93.	2.2	24
4	Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Nutrition, 2021, 83, 111092.	2.4	41
5	Systematic review with metaâ€analysis: The effect of vitamin E supplementation in adult patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 311-319.	2.8	46
6	Evaluation of subclinical cardiac damage in biopsy-proven nonalcoholic fatty liver disease: a systematic review and meta-analysis. Annals of Gastroenterology, 2021, 34, 424-430.	0.6	3
7	Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology, 2021, 77, 397-407.	1.9	29
8	American, European and international hypertension guidelines: Time to shake hands?. International Journal of Cardiology: Hypertension, 2021, 8, 100075.	2.2	12
9	Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation. Current Pharmaceutical Design, 2021, 27, 1298-1310.	1.9	1
10	Risk Models and Scores of Cardiovascular Disease in Patients with Diabetes Mellitus. Current Pharmaceutical Design, 2021, 27, 1245-1253.	1.9	3
11	Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap. Current Pharmaceutical Design, 2021, 27, 1068-1079.	1.9	2
12	Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis. Endocrine-Related Cancer, 2021, 28, 325-335.	3.1	6
13	Estimated Arterial Stiffness and Prediction of Vascular Aging: The Rising of a New Era. Current Pharmaceutical Design, 2021, 27, 1871-1877.	1.9	1
14	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. Current Pharmaceutical Design, 2021, 27, 2537-2544.	1.9	1
15	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. International Journal of Cardiology, 2021, 345, 119-124.	1.7	19
16	Hypertension in Obesity: Novel Insights. Current Hypertension Reviews, 2020, 16, 30-36.	0.9	21
17	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. Journal of Hypertension, 2020, 38, 377-386.	0.5	7
18	Reduction in environmental noise during COVIDâ€19 pandemic and cardiovascular disease: A mystery for further investigation. Journal of Clinical Hypertension, 2020, 22, 1947-1948.	2.0	7

#	Article	IF	CITATIONS
19	Unmasking hypertension in children and adolescents with sickle/betaâ€ŧhalassemia. Journal of Clinical Hypertension, 2020, 22, 1444-1449.	2.0	5
20	Blood pressure response to noise in children and adolescents. Journal of Clinical Hypertension, 2020, 22, 1442-1443.	2.0	4
21	Masked and white coat hypertension, the double trouble of large arteries: A systematic review and metaâ€analysis. Journal of Clinical Hypertension, 2020, 22, 802-811.	2.0	17
22	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. Lipids in Health and Disease, 2020, 19, 114.	3.0	6
23	Î <b>F</b> e European and American guidelines in the detection of hypertension phenotypes: The no-deal under the light of clinical practice. European Journal of Preventive Cardiology, 2020, , 2047487320935559.	1.8	1
24	The challenge of simplifying blood pressure screening in children and adolescents. Journal of Clinical Hypertension, 2020, 22, 876-878.	2.0	4
25	Non-Vitamin K Antagonist Oral Anticoagulants in Pulmonary Embolism: An Overview of Systematic Reviews. Current Pharmaceutical Design, 2020, 26, 2686-2691.	1.9	3
26	The flipside of hydralazine in pregnancy: A systematic review and meta-analysis. Pregnancy Hypertension, 2020, 19, 177-186.	1.4	11
27	Mobile Clinical Decision Support System for the Management of Diabetic Patients With Kidney Complications in UK Primary Care Settings: Mixed Methods Feasibility Study. JMIR Diabetes, 2020, 5, e19650.	1.9	7
28	<p>The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date</p> . Drug Design, Development and Therapy, 2019, Volume 13, 2985-2996.	4.3	14
29	Masked hypertensives: A disguised arterial stiffness population. Journal of Clinical Hypertension, 2019, 21, 1473-1480.	2.0	12
30	Obesity and season as determinants of high blood pressure in a school-based screening study. Journal of Human Hypertension, 2019, 33, 277-285.	2.2	6
31	Subclinical Arterial Damage in Children and Adolescents with Type 1 Diabetes: A Systematic Review and Metaâ€Analysis. Pediatric Diabetes, 2019, 20, 668-677.	2.9	25
32	Comparison of the SphygmoCor XCEL device with applanation tonometry for pulse wave velocity and central blood pressure assessment in youth. Journal of Hypertension, 2019, 37, 30-36.	0.5	27
33	Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. Scandinavian Cardiovascular Journal, 2019, 53, 48-54.	1.2	6
34	Body composition and arterial stiffness in pediatric patients with chronic kidney disease. Pediatric Nephrology, 2019, 34, 1253-1260.	1.7	14
35	Legacy effect on mortality in antihypertensive drug comparison trials. Journal of Hypertension, 2019, 37, 1532-1534.	0.5	1
36	A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension. Journal of Human Hypertension, 2019, 33, 188-201.	2,2	11

3

#	Article	IF	CITATION
37	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1427-1440.	0.5	86
38	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1441-1455.	0.5	44
39	Comparison Among Recommendations for the Management of Arterial Hypertension Issued by Last US, Canadian, British and European Guidelines. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 9-16.	2.2	12
40	Overview of Systematic Reviews of Non–Vitamin K Oral Anticoagulants in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004769.	2.2	21
41	Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score. American Journal of Hypertension, 2018, 31, 1197-1204.	2.0	13
42	Screening for Malnutrition Among People Accessing Health Services at Greek Public Hospitals: Results From an Observational Multicenter Study. Journal of Parenteral and Enteral Nutrition, 2017, 42, 014860711772274.	2.6	9
43	Obesity-Induced Hypertension: New Insights. Current Pharmaceutical Design, 2017, 23, 4620-4625.	1.9	10
44	Markers of Early Vascular Ageing. Current Pharmaceutical Design, 2017, 23, 3200-3204.	1.9	17